Beyond barriers: when neurons act immune and immunity acts neural [0.03%]
跨越障碍：当神经元表现得像免疫细胞而免疫系统表现得像神经系统时
Sang Wha Kim,Seung Hyeok Seok
Sang Wha Kim
A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib [0.03%]
奥希替尼一线治疗失败的EGFR突变晚期非小细胞肺癌患者的前瞻性、多中心综合基因谱特征研究
Yuankai Shi,Dongqing Lv,Weineng Feng et al.
Yuankai Shi et al.
Osimertinib, the first approved third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), exhibits notable efficacy in EGFR-mutant non-small cell lung cancer (NSCLC). This is a prospective, multicenter, compr...
Integrative analysis of non-small cell lung cancer identifies Jumonji domain-containing 6/ETS homologous factor axis as a target to overcome radioresistance [0.03%]
整合分析非小细胞肺癌识别Jumonji结构域包含6/ETS同源因子轴作为克服放射耐药性的靶点
Manni Wang,Li Xu,Aqu Alu et al.
Manni Wang et al.
Radiation therapy (RT) is a key treatment strategy for lung cancer, yet its efficacy is frequently compromised by radioresistance. The combination of RT with targeted therapies enhances treatment outcomes for non-small cell lung cancer (NSC...
MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer [0.03%]
黏蛋白1使非小细胞肺癌上皮-间充质转化相关酪氨酸激酶抑制剂耐药炎症记忆化
Shinkichi Takamori,Naoki Haratake,Atrayee Bhattacharya et al.
Shinkichi Takamori et al.
Resistance of NSCLCs to osimertinib, an EGFR tyrosine kinase inhibitor (TKI), is mediated by pleotropic mechanisms that pose a significant challenge for subsequent treatment. We report that the oncogenic MUC1-C/M1C protein confers resistanc...
Pulsed electromagnetic fields inhibit atherosclerosis by regulating pyroptosis through membrane tension-mediated mechanosensitive channels [0.03%]
脉冲电磁场通过膜张力介导的机械敏感性通道调节细胞焦亡从而抑制动脉粥样硬化
Hongxin Cheng,Qing Zhang,Wen Zhong et al.
Hongxin Cheng et al.
Atherosclerosis serves as the core pathological basis of cardiovascular, cerebrovascular, and peripheral arterial diseases, posing a serious threat to human health. However, current mainstream treatments such as statin drugs and stent impla...
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges [0.03%]
靶向KRAS突变：协调癌症进化和治疗挑战
Khalil Choucair,Hafsa Imtiaz,Md Hafiz Uddin et al.
Khalil Choucair et al.
Activating KRAS mutations are highly relevant to various cancers, and KRAS is the most frequently altered oncogenic protein in solid tumors. While historically considered undruggable, two KRASG12C inactive state-selective inhibitors are cur...
Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2) [0.03%]
帕博利珠单抗(PD-1抗体)联合术前放化疗治疗食管鳞癌的I/II期临床试验(PALACE-2)
Chengqiang Li,Yichao Han,Shengguang Zhao et al.
Chengqiang Li et al.
The role of preoperative anti-PD-1 antibody (pembrolizumab) plus chemoradiotherapy (PPCT) in locally advanced, resectable esophageal squamous cell carcinoma (ESCC) is still unclear. We aimed to investigate the therapeutic effect and safety ...
Induction of cuproptosis enhances sensitivity and overcomes resistance to osimertinib in lung cancer [0.03%]
诱导铜死亡可增强肺癌对奥希替尼的敏感性并克服耐药问题
Yi-Bo Gao,Jia-Ming Xie,Yan-Nan Yang et al.
Yi-Bo Gao et al.
Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: a randomized, double-blind, placebo-controlled phase Ib/IIa trial [0.03%]
抗CD38单克隆抗体CM313治疗系统性红斑狼疮 Ib/IIa期随机双盲安慰剂对照临床试验
Jiuliang Zhao,Changsong Lin,Qibing Xie et al.
Jiuliang Zhao et al.
CD38 is highly expressed on various immune cells, including long-lived plasma cells, making it a potential therapeutic target in autoimmune diseases. This phase Ib/IIa study aimed to explore the safety, pharmacokinetics, pharmacodynamics, a...
Tissue-adapted Tregs harness inflammatory signals to promote intestinal repair from therapy-related injury [0.03%]
适应组织的Treg细胞利用炎症信号促进由治疗引起的肠道损伤修复
Julius C Fischer,Sascha Göttert,Maximilian Giller et al.
Julius C Fischer et al.
Intestinal stem cells (ISCs) promote tissue repair after genotoxic or immune-mediated injury. However, ISCs are particularly sensitive to various stressors and primary targets of overwhelming immune responses, such as interferon γ (IFNγ)-...